Anti-Alpha-synuclein 抗体 [syn211] (ab80627)

ab80627 を使用した論文を発表された方は、こちらまでお知らせください。データシートに掲載させていただきます。

ab80627 は 7 報の論文で使用されています。

  • Betzer C  et al. Alpha-synuclein aggregates activate calcium pump SERCA leading to calcium dysregulation. EMBO Rep 19:N/A (2018). PubMed: 29599149
  • Doucet M  et al. Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles. PLoS One 12:e0181844 (2017). WB . PubMed: 28797124
  • Karampetsou M  et al. Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice. Sci Rep 7:16533 (2017). PubMed: 29184069
  • Landeck N  et al. A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein. Mol Neurodegener 11:61 (2016). WB ; Mouse, Rat, Human . PubMed: 27549140
  • Price DL  et al. Longitudinal live imaging of retinal a-synuclein::GFP deposits in a transgenic mouse model of Parkinson's Disease/Dementia with Lewy Bodies. Sci Rep 6:29523 (2016). IHC-FrFl ; Mouse . PubMed: 27389831
  • Ryan BJ  et al. a-Synuclein and mitochondrial bioenergetics regulate tetrahydrobiopterin levels in a human dopaminergic model of Parkinson disease. Free Radic Biol Med 67C:58-68 (2013). PubMed: 24148766
  • Giasson BI  et al. A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease. J Neurosci Res 59:528-33 (2000). WB, IP ; Human . PubMed: 10679792

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

登録